The PBPK model outlined above was evaluated on seven compounds, comparing the predicted pharmacokinetics to clinical pharmacokinetic data. Each subsection that follows will contain an introduction to the compound under consideration, a description of the PBPK model in a healthy population, and the subsequent extension to a population with CKD.